drugset / Trial / NCT07373054

Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia

NCT07373054

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Androgenic Alopecia(AGA) is a highly prevalent condition for which existing pharmacological and surgical interventions present limitations and side effects, creating a clinical need for safer and more effective therapies. In response, human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) have emerged as a cell-free therapeutic strategy. Characterized by their rich bioactive components, absence of tumorigenic risk, and high safety profile, hUCMSC-Exos represent a promising approach for hair regeneration. This study aims to evaluate the safety and efficacy of hUCMSC-Exos combined with automated microneedle delivery for treating AGA. By utilizing innovative lyophilization technology to maintain exosomal bioactivity and employing precision microneedle systems for enhanced delivery, this research seeks to provide a new generation solution for androgenic alopecia treatment.

Timeline

Start
2025-11-06
Primary completion
2026-07-01
Completion
2027-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Minoxidil Small molecule 1 ml Topical
Comparator Minoxidil Small molecule 5 % Topical
Subject hUCMSC-Exos Other / unclassified 3 ml Topical

Indications